Stay updated with breaking news from Morphosys Ag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More than 30 years after entering the scene as a first-generation monoclonal antibody pioneer, Morphosys AG is to be acquired by Novartis AG for €2.7 billion (US$2.9 billion). The all-cash deal, announced after Nasdaq closed on Feb. 5, will see Novartis paying €68 per share, a premium of 94% to the average daily price in the month leading up to Jan. 25, when rumors of a takeover started swirling.
European stocks finished lower Tuesday, with the Stoxx Europe 600 index falling 0.30% to 457.04. The French CAC 40 index fell 0.21% to 7,250.13, the FTSE 100...
European stocks increased Wednesday, as the Stoxx Europe 600 index finished up 0.30% to 457.24. The French CAC 40 index increased 0.43% to 7,260.73, the...
European stocks finished flat Tuesday, with the Stoxx Europe 600 index closing at 455.85. The French CAC 40 index fell 0.24% to 7,229.45, the FTSE 100 index...
Key Insights Significantly high institutional ownership implies MorphoSys' stock price is sensitive to their trading...